John Pinching

England, United Kingdom

Editor at PharmaTimes

Featured in: Favicon

pharmatimes.com Favicon

pmlive.com Favicon

technologymagazine.com Favicon

fintechmagazine.com Favicon

sustainabilitymag.com

Articles

Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease

2 days ago | pharmatimes.com | John Pinching

Herantis Pharma has dosed the first patients in the final cohort of its phase 1b clinical trial assessing HER-096, a disease-modifying treatment for Parkinson’s disease. The study aims to evaluate the drug’s safety, tolerability and pharmacokinetics while exploring biomarkers linked to the condition. HER-096 is a first-in-class synthetic peptidomimetic designed to mimic cerebral dopamine neurotropic factor (CDNF) protein.
Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment

2 days ago | pharmatimes.com | John Pinching

Kaerus Bioscience has received orphan drug and rare paediatric drug designations from the FDA for KER-0193, its lead candidate targeting fragile x syndrome (FXS). The announcement follows a successful phase 1 trial confirming the drug’s safety and promising pharmacokinetics. FXS is the most common cause of inherited autism and intellectual disability, affecting approximately 1 in 7,000 males and 1 in 11,000 females. There are currently no approved treatments for the condition.
Gergely Sved - PharmaTimes

3 days ago | pharmatimes.com | John Pinching

Ellab, the provider of validation, monitoring and calibration services and solutions, has appointed Gergely Sved as its new Chief Executive Officer (CEO), following the departure of Ludvig Enlund. Gergely is a highly experienced healthcare and life sciences executive. Most recently, he served as Executive Vice President and Group President for the Healthcare and Life Sciences division at Ecolab Inc, a global leader in water, hygiene and infection prevention solutions and services.
Rein Therapeutics initiates renew phase 2 trial for IPF treatment

3 days ago | pharmatimes.com | John Pinching

Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial, assessing LTI-03 as a potential treatment for idiopathic pulmonary fibrosis (IPF). The study will enrol up to 120 patients across 50 global sites, with topline results expected in the first half of 2026. LTI-03 is a novel, multi-pathway, Caveolin-1-related peptide designed to improve alveolar epithelial cell survival and inhibit profibrotic signalling.
Fiona Smith-Laittan

4 days ago | pharmatimes.com | John Pinching

Fiona Smith-Laittan, Vice President of Global Health Strategy and Partnerships at GlaxoSmithKline (GSK), has been appointed Chair of Cambridge Global Health Partnerships (CGHP). Fiona, who has led GSK’s Global Health Strategy and Partnerships team since 2019, said: “CGHP’s purpose, strategy and activity is aligned to what I care about most, in an area where I bring significant experience, insights and a strong network.
Apiary invests in life sciences marketing specialist performance-io

4 days ago | pharmatimes.com | John Pinching

Apiary Capital has completed its investment in performance-io (PIO), a leading life sciences performance marketing and search engine optimization agency, supporting its international expansion and service growth. London-based PIO employs more than 60 people globally, with teams across the UK, US, India, Japan and South Africa. Since launching in 2018, it has established itself as the first specialist SEO agency operating in the regulated pharma space.
Amgen’s Tepezza granted marketing authorisation in the UK

1 week ago | pharmatimes.com | John Pinching

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza (teprotumumab) as the first licensed treatment for adults with moderate-to-severe thyroid eye disease (TED). TED affects around 50,000 people in the UK, causing eye bulging, double vision, pain and swelling, and significantly impacting patients’ quality of life.
iOnctura starts randomised phase 1/2 trial in lung cancer treatment

1 week ago | pharmatimes.com | John Pinching

iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, with or without docetaxel, in advanced non-small cell lung cancer (NSCLC). The first patient has been dosed in the study, which aims to evaluate the safety of the drug combination and its potential in overcoming resistance to standard immunotherapy. NSCLC is the most common type of lung cancer and accounts for around one in five cancer deaths globally.
MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d

1 week ago | pharmatimes.com | John Pinching

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. TK2d is a rare genetic disorder caused by a mutation in the TK2 gene. This leads to mitochondrial DNA depletion, resulting in severe and progressive muscle weakness.
PharmaTimes Clinical Researcher of the Year – The Americas Awards - PharmaTimes

1 week ago | pharmatimes.com | John Pinching

Demonstrate your skill and prowess by entering this year's awards! For 2025, The 2025 PharmaTimes Clinical Researcher of the Year – The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to assess the required skills and competencies to be an organised and competent Clinical Trial Administrator (CTA).